Djureinovic, Dijana
Weiss, Sarah A.
Krykbaeva, Irina
Qu, Rihao
Vathiotis, Ioannis
Moutafi, Myrto
Zhang, Lin
Perdigoto, Ana L.
Wei, Wei
Anderson, Gail
Damsky, William
Hurwitz, Michael
Johnson, Barbara
Schoenfeld, David
Mahajan, Amit
Hsu, Frank
Miller-Jensen, Kathryn
Kluger, Yuval
Sznol, Mario
Kaech, Susan M.
Bosenberg, Marcus
Jilaveanu, Lucia B.
Kluger, Harriet M.
Funding for this research was provided by:
Wenner-Gren Stiftelserna
National Institutes of Health (K12CA215119, NRSAF30GR10226, U01CA238728, U01CA238728, U01CA238728, RO1 CA204002, K12CA215119)
Yale SPORE in Lung Cancer (P50CA196530)
Yale Calabresi Immuno-Oncology Training Program (K12CA215110)
Helleneic Society of Medical Oncologists
Yale SPORE in Skin Cancer, USA (P50CA121974, P50CA121974, P50CA121974, P50CA121974)
Article History
Received: 8 March 2023
Accepted: 19 October 2023
First Online: 14 November 2023
Declarations
:
: This study was approved by the Yale University Institutional Review Board and conducted in agreement with ethical guidelines as outlined by the U.S. Common Rule and the Declaration of Helsinki. All participants provided written informed consent. Animal studies were approved by and done in accordance with Yale’s Institutional Animal Care and Use Committee.
: Not applicable.
: D.D reports grants from Wenner-Gren Foundations during the conduct of the study. S.A.W reports grants from the Yale Calabresi Immuno-oncology Training Program (K12CA215110), a Career Enhancement Program Grant from the Yale SPORE in Lung Cancer (P50 CA196530) as well as financial disclosures from Lyell Immunopharma (advisory board). I. K reports grant from National Institutes of Health NRSA F30 GR10226. M.M reports grant from Hellenic Society of Medical Oncologists (HESMO). W.W reports research funding from Taketa. W.D reports personal fees from Eli Lilly, Pfizer, Twi Biotechnology, Incyte, and Epiarx Diagnostics and has received research funding from Pfizer, Advanced Cell Diagnostics/Bio-techne, AbbVie, Incyte, Boehringer Ingelheim, Bristol Myers Squibb and licensing fees from EMD/Sigma/Millipore. M.H reports financial disclosures from Arvinas and other support from Exelixis, Janssen, CRISPR Therapeutics, Tscan, Pliant and research funding from Alpine, Achilles Therapeutics, Apexigen, Arrowhead, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, CRISPR Therapeutics, Corvus, Eli Lilly, Endocyte, Fate Therapeutics, Genentech, Genmab, GSK, Innocrin, Iovance, KSQ, Merck, Nektar Therapeutics, Novartis, Pfizer, Progenics, Sanofi Aventis, Seattle Genetics, Tmunity, Torque, Tscan. D.S reports grants from T32 CA233414. A.M reports other support from Gilead, Bristol Myers Squib, Bausch, Atara, Teva and Aurinia pharmaceuticals outside the submitted work. K.M.J reports grants from U01CA238728. Y.K reports grants from the Yale SPORE in Skin Cancer P50 CA121974. M.S reports other support from Adaptive Biotechnologies, Amphivena, Intensity, Actym, Evolveimmune, Nextcure, Repertoire, Oncohost, Asher, Rootpath, Johnson and Johnson and Glaxo-Smith Kline, Biond, Adaptimmune, Bristol-Myers, Biontech, Simcha, Verastem, Pfizer, Innate pharma, PIO Therapeutics, Kadmon – Sanofi, Pierre-Fabre, Incyte, Alligator, Ocellaris-Lilly, Numab, Immunocore, Adagene, Kanaph, iTEOS, Genocea, Sapience, Targovax, Molecular Partners, Ontario Institute for Cancer Research, Jazz Pharmaceuticals, Gilead, Tessa, Stcube, Oncosec, Regeneron, Astra Zeneca, Agenus, Idera, Apexigen, Rubius, Genentech-Roche, Boston Pharmaceuticals, Servier, Dragonfly, Xilio, Normunity. S.K reports grants from the Yale SPORE in Skin Cancer P50 CA121974 and U01CA238728. M.B reports grants from the Yale SPORE in Skin Cancer P50 CA121974 and U01CA238728. L.J reports grants from R01CA204002. H. K reports grants from from the Yale SPORE in Skin Cancer P50 CA121974, R01 CA227472, R01 CA216846, NIH grants K12CA215119, institutional research grants from Merck, Bristol Myers Squibb and Apexigen and financial support from Iovance, Celldex, Merck, Elevate Bio, Instil Bio, Bristol Myers Squibb, Clinigen, Shionogi, Chemocentryx, Calithera, Signatero, Gigagen, GI reviewers, Seranova, Pliant Therapeutics. Remaining authors have declared no conflicts of interest.